Literature DB >> 28631895

Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.

Paola Cambiaso1, Stefania Galassi2, Melania Palmiero1, Angela Mastronuzzi3, Francesca Del Bufalo3, Rossella Capolino4, Antonella Cacchione3, Paola S Buonuomo4, Michaela V Gonfiantini4, Andrea Bartuli4, Marco Cappa1, Marina Macchiaiolo4.   

Abstract

In children with neurofibromatosis type 1 (NF1) and optic pathways glioma (OPG), growth hormone (GH) excess has been rarely reported and mainly associated to central precocious puberty. The aim of our study is to evaluate the prevalence of GH excess, the association with central precocious puberty, the relation with tumor site and the evolution over time in a large cohort of children with NF1 and OPG. Sixty-four NF1 children with OPG were evaluated. Patients with stature and/or height velocity >2 SD for age were studied for GH secretion. Seven out of 64 children (10.9%) with NF1 and optic pathways glioma showed GH excess, isolated in 5 cases and associated to central precocious puberty in 2. All the children with GH excess had a tumor involving the chiasma. Children with GH excess underwent medical treatment with lanreotide and a minimum clinical/biochemical follow up of 2 years is reported. The present study demonstrates that GH excess should be considered as a relative frequent endocrine manifestation in NF1 patients, similarly to central precocious puberty. Therefore, these patients should undergo frequent accurate auxologic evaluations. On the other hand, an increase in height velocity in children with NF1, even despite normal ophthalmological exams, can suggest the presence of OPG and therefore represents an indication to perform brain MRI.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  gigantism; neurofibromatosis 1; optic pathways glioma

Mesh:

Substances:

Year:  2017        PMID: 28631895     DOI: 10.1002/ajmg.a.38308

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

1.  Optic pathway glioma and endocrine disorders in patients with and without NF1.

Authors:  Merav Gil Margolis; Michal Yackobovitz-Gavan; Helen Toledano; Ariel Tenenbaum; Roni Cohen; Moshe Phillip; Shlomit Shalitin
Journal:  Pediatr Res       Date:  2022-05-10       Impact factor: 3.756

2.  Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.

Authors:  Fady Hannah-Shmouni; Giampaolo Trivellin; Pablo Beckers; Lefkothea P Karaviti; Maya Lodish; Christina Tatsi; Adekunle M Adesina; Fotini Adamidou; Gesthimani Mintziori; Jami L Josefson; Martha Quezado; Constantine A Stratakis
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

3.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

Review 4.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

Review 5.  The Genetics of Pituitary Adenomas.

Authors:  Christina Tatsi; Constantine A Stratakis
Journal:  J Clin Med       Date:  2019-12-21       Impact factor: 4.241

Review 6.  The clinical aspects of pituitary tumour genetics.

Authors:  Judit Dénes; Márta Korbonits
Journal:  Endocrine       Date:  2021-02-04       Impact factor: 3.633

7.  Ovarian cell tumor in a child with neurofibromatosis type 1.

Authors:  Lujain Majdi Qutub; Abdulmoein Eid Al-Agha
Journal:  Ann Afr Med       Date:  2022 Apr-Jun

Review 8.  Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis.

Authors:  Omid Yousefi; Pouria Azami; Mohammadmahdi Sabahi; Rocco Dabecco; Badih Adada; Hamid Borghei-Razavi
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

Review 9.  Genetics of Acromegaly and Gigantism.

Authors:  Anna Bogusławska; Márta Korbonits
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.